Newlink Genetics Corporation
(NASDAQ : NLNK)

( )
NLNK PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Loading NLNK News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.00%167.451.2%$752.43m
INCYIncyte Corporation
0.00%141.281.7%$625.70m
GILDGilead Sciences, Inc.
0.00%67.831.0%$594.24m
CELGCelgene Corporation
0.00%123.371.0%$512.15m
BIIBBiogen Inc.
0.00%277.871.3%$452.42m
REGNRegeneron Pharmaceuticals, Inc.
0.00%369.142.1%$317.75m
KITEKite Pharma, Inc.
0.00%76.3818.8%$210.13m
ALXNAlexion Pharmaceuticals, Inc.
0.00%120.081.6%$205.79m
TSROTESARO, Inc.
0.00%155.7816.1%$177.45m
ILMNIllumina, Inc.
0.00%167.793.7%$165.24m
ESPREsperion Therapeutics, Inc.
0.36%39.1518.7%$165.09m
AUPHAurinia Pharmaceuticals Inc.
0.00%8.536.3%$148.77m
CLVSClovis Oncology, Inc.
0.00%67.1817.5%$141.46m
VRTXVertex Pharmaceuticals Incorporated
0.00%90.042.2%$134.96m
EXELExelixis, Inc.
0.00%20.487.0%$106.18m

Company Profile

NewLink Genetics Corp. is a biopharmaceutical company, which focuses on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. The company's products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189 and IDO Pathway Inhibitors. NewLink Genetics was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.